Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment.

[1]  E. Karlsson,et al.  Captopril and spironolactone therapy in patients with refractory congestive heart failure , 1992 .

[2]  F. Zannad.  Vascular and cardiac actions of aldosterone and spironolactone. , 1991, Zeitschrift fur Kardiologie.

[3]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[4]  K. Swedberg,et al.  Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. , 1990, The American journal of cardiology.

[5]  G. Lamas,et al.  Role of left ventricular dysfunction in neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction , 1990 .

[6]  C Dacquet,et al.  Interactions of spironolactone with (+)‐[3H]‐isradipine and (−)‐[3H]‐desmethoxyverapamil binding sites in vascular smooth muscle , 1990, British journal of pharmacology.

[7]  D. Schohn,et al.  Effects of a potassium-sparing/thiazide diuretic combination on cardiovascular reactivity to vasopressor agents. , 1990, The American journal of cardiology.

[8]  J. Bigger.  Cardiac electrophysiologic effects of moricizine hydrochloride. , 1990, The American journal of cardiology.

[9]  K. Swedberg,et al.  Tolerability of enalapril in congestive heart failure. , 1988, The American journal of cardiology.

[10]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[11]  P. Pacaud,et al.  Spironolactone inhibition of contraction and calcium channels in rat portal vein , 1987, British journal of pharmacology.

[12]  P. Poole‐Wilson,et al.  Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. , 1987, British heart journal.

[13]  A. Richards,et al.  Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure. , 1986, Australian and New Zealand journal of medicine.

[14]  B. W. East,et al.  Captopril in heart failure. A double blind controlled trial. , 1984, British heart journal.

[15]  J. Drayer,et al.  Interactions of Mineralocorticoids and Pressor Agents in Vascular Smooth Muscle , 1983, Hypertension.

[16]  J. Biollaz,et al.  Antihypertensive Therapy with MK 4211: Angiotensin II‐Renin Relationships to Evaluate Efficacy of Converting Enzyme Blockade , 1982, Journal of cardiovascular pharmacology.

[17]  J. Staessen,et al.  Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. , 1981, The Journal of endocrinology.

[18]  E. Deroubaix,et al.  Effect of a spirolactone derivative, sodium canrenoate, on mechanical and electrical activities of isolated rat myocardium. , 1974, The Journal of pharmacology and experimental therapeutics.

[19]  R. L. Wolf,et al.  The effect of spironolactone on digital vascular reactivity in essential hypertension. , 1968, American heart journal.

[20]  B. Little,et al.  Splanchnic Extraction and Clearance of Aldosterone in Subjects with Minimal and Marked Cardiac Dysfunction1 , 1965 .